Abstract
Background Hypertrophic cardiomyopathy (HCM) is caused by rare variants in sarcomere-encoding genes, but little is known about the clinical significance of these variants in the general population.
Methods We compared outcomes and cardiovascular phenotypes in UK Biobank participants with whole exome sequencing stratified by sarcomere-encoding variant status.
Results The prevalence of rare variants (allele frequency <0.00004) in HCM-associated sarcomere-encoding genes in 200,584 participants was 2.9% (n=5,727; 1 in 35), of which 0.24% (n=474, 1 in 423) were pathogenic or likely pathogenic variants (SARC-P/LP). SARC-P/LP variants were associated with increased risk of death or major adverse cardiac events compared to controls (HR 1.68, 95% CI 1.37-2.06, p<0.001), mainly due to heart failure (HR 4.40, 95% CI 3.22-6.02, p<0.001) and arrhythmia (HR 1.55, 95% CI 1.18-2.03, p=0.002). In 21,322 participants with cardiac magnetic resonance imaging, SARC-P/LP were associated with increased left ventricular maximum wall thickness (10.9±2.7 vs 9.4±1.6 mm, p<0.001) and concentric remodelling (mass/volume ratio: 0.63±0.12 vs 0.58±0.09 g/mL, p<0.001), but hypertrophy (≥13mm) was only present in 16% (n=7/43, 95% CI 7-31%). Other rare sarcomere-encoding variants had a weak effect on wall thickness (9.5±1.7 vs 9.4±1.6 mm, p=0.002) with no combined excess cardiovascular risk (HR 1.00 95% CI 0.92-1.08, p=0.9).
Conclusions In the general population, SARC-P/LP variants have low aggregate penetrance for overt HCM but are associated with an increased risk of adverse cardiovascular outcomes and a sub-clinical cardiomyopathic phenotype. In contrast, rare sarcomeric variants that do not meet criteria to be classified as P/LP appear to have minimal clinical impact.
Competing Interest Statement
J.S.W. has consulted for MyoKardia, Inc. S.A.C holds shares in Enleofen Bio Pte. Ltd.
Funding Statement
The study was supported by the Medical Research Council, UK (MC-A651-53301); National Institute for Health Research (NIHR) Imperial College Biomedical Research Centre; NIHR Royal Brompton Cardiovascular Biomedical Research Unit; British Heart Foundation (NH/17/1/32725, RG/19/6/34387, RE/18/4/34215); Fondation Leducq (16 CVD 03); Wellcome Trust (107469/Z/15/Z, 200990/A/16/Z); Academy of Medical Sciences (SGL015/1006; A.D.M.); Mason Medical Research Trust grant (A.D.M.); SmartHeart EPSRC Programme Grant (EP/P001009/1; W.B. and D.R.); and a Rosetrees and Stoneygate Imperial College Research Fellowship (N.W.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the National Research Ethics Service (11/NW/0382). A statement on research ethics approval for this biobank is available online (https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics). Approval from UK Biobank was received to use the data in the present work under terms of access approval number 40616.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Abbreviations
- ACMG
- American College of Medical Genetics and Genomics
- AF
- atrial fibrillation
- CC
- CardioClassifier
- CMR
- cardiovascular magnetic resonance imaging
- DBP
- diastolic blood pressure
- FAF
- filtering allele frequency
- FD
- fractal dimension
- HCM
- hypertrophic cardiomyopathy
- LV
- left ventricle
- LVEDV
- left ventricular end-diastolic volume
- LVEF
- left ventricular ejection fraction
- LVESV
- left ventricular end-systolic volume
- LVH
- left-ventricular hypertrophy
- MAF
- minor allele frequency
- SARC-P/LP
- pathogenic or likely pathogenic variants in sarcomere-encoding genes
- SARC-NEG
- genotype negative / no rare variants in sarcomere-encoding genes
- SARC-IND
- indeterminate variants in HCM-associated sarcomere-encoding genes (rare variants that do not meet criteria for pathogenic/likely pathogenic annotation)
- SBP
- systolic blood pressure
- UKBB
- UK Biobank
- WT
- wall thickness
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos